Subtle Medical has secured FDA 510(k) clearance for SubtleHD(CT), an AI-powered image enhancement tool that the Menlo Park company says reduces noise and boosts low-contrast detectability on computed tomography (CT) scans, regardless of the scanner vendor or vintage.
SubtleHD(CT) targets the messy reality of mixed CT fleets
The new clearance, announced on June 10, marks Subtle Medical's first CT product and brings its AI image enhancement portfolio to all three major modalities — MRI, PET and now CT. Hospitals and imaging centers typically operate fleets that mix recent premium scanners with older systems, and SubtleHD(CT) is designed to deliver more uniform image quality across both. Subtle says the algorithm helps radiologists detect subtle low-contrast structures that are easily lost in noisy datasets, particularly at lower radiation doses.
Eleventh clearance for an AI imaging company on the rise
SubtleHD(CT) is Subtle Medical's 11th FDA-cleared product. The company says its software has now been deployed on more than 1,300 scanners worldwide, building on a portfolio that already includes the recently cleared SubtleHD(PET) and the earlier SubtleMR offering. "Health-care organizations are looking for ways to improve imaging performance while maximizing the value of the infrastructure they already have," said Ohad Arazi, Subtle Medical's chief executive officer. "With SubtleHD(CT) we're extending our expertise in AI-powered image enhancement to CT and taking another step toward our vision of helping providers enhance image quality across the imaging enterprise."
Why the CT expansion matters
The clearance lands as CT volume continues to rise faster than radiology staffing, putting pressure on hospitals to extract better images from existing fleets rather than buy new scanners. Subtle's bet is that vendor-agnostic AI enhancement, layered on top of installed hardware, can deliver near-premium image quality at a fraction of the capital cost. The launch follows Subtle Medical's recent $33M Series C and the appointment of Arazi as CEO, both aimed at scaling deployment into more health systems globally. Competition is intensifying — GE HealthCare's recent AI-enabled MIM Contour ProtégéAI+ 2.0 clearance and a broader surge in FDA-cleared imaging AI in 2025 and early 2026 underscore the rapid commercialization of radiology AI.
Reporting based on coverage from Diagnostic Imaging, PRNewswire and Applied Radiology.